HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, June 12 (HealthDay News) -- The oncofetal protein SALL4 is expressed in a subgroup of patients with hepatocellular carcinoma, with overexpression of proliferative and metastatic genes observed in SALL4-positive hepatocellular carcinomas, according to a study published in the June 13 issue of the New England Journal of Medicine.
Kol Jia Yong, from the Cancer Science Institute of Singapore, and colleagues screened specimens from patients with primary hepatocellular carcinoma for SALL4 expression and conducted a clinicopathological analysis. The role of SALL4 in hepatocarcinogenesis and its potential as a molecular target for therapy was assessed.
The researchers found that the oncofetal protein SALL4 was silenced in the adult liver, but was reexpressed in a subgroup of patients with hepatocellular carcinoma and an unfavorable prognosis. In SALL4-positive hepatocellular carcinomas, enrichment of progenitor-like gene signatures was observed, with overexpression of proliferative and metastatic genes noted in gene-expression analysis. The critical role of SALL4 in cell survival and tumorigenicity was confirmed in loss-of-function studies. In in-vivo xenograft models, blocking SALL4-corepressor interactions released the phosphatase and tensin homologue protein suppression and inhibited tumor formation.
"SALL4 is a marker for a progenitor subclass of hepatocellular carcinoma with an aggressive phenotype," the authors write. "The absence of SALL4 expression in the healthy adult liver enhances the potential of SALL4 as a treatment target in hepatocellular carcinoma."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on June 03, 2022